ReviewJournal of gastric cancer2014
Imaging of Gastric Cancer Metabolism Using 18 F-FDG PET/CT.
Review in Journal of gastric cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Korean Practice Guidelines for Gastric Cancer 2024: An Evidence-based, Multidisciplinary Approach (Update of 2022 Guideline).Journal of gastric cancer · 2025Guideline
- Association between neutrophil-lymphocyte ratio and lymph node metastasis in gastric cancer: A meta-analysis.Medicine · 2022Pooled it
- Gallium-68-labeled fibroblast activation protein inhibitor PET in gastrointestinal cancer: insights into diagnosis and management.European journal of nuclear medicine and molecular imaging · 2022Trial
- Gastrointestinal cancer with indeterminateOncology letters · 2026Article
- FAPI PET/CT shows favorable potential for the evaluation of gallbladder cancer: a prospective study comparing [EJNMMI research · 2026Article
- 18F-FDG-PET/CT-negative gastric cancer employs glutamine-based gluconeogenesis and fatty acid oxidation to support tumor growth.Cell death & disease · 2026Article
- Plasma-based digital PCR assay for early detection of gastric cancer using multiple methylation biomarkers.Scientific reports · 2025Article
- Impact ofMolecular imaging and radionuclide therapy · 2025Article
- Use of 18-Fluorodeoxyglucose Positron Emission Tomography and Near-Infrared Fluorescence-Guided Imaging Surgery in the Treatment of a Gastric Tumor in a Dog.Animals : an open access journal from MDPI · 2024Article
- The role of dysregulated metabolism and associated genes in gastric cancer initiation and development.Translational cancer research · 2024Review
- Nuclear medicine radiomics in digestive system tumors: Concept, applications, challenges, and future perspectives.View (Beijing, China) · 2023Article
- The additional role of [68Ga]Ga-FAPI-04 PET/CT in patients with unknown primary lesion with a negative or equivocal [18F]FDG.European journal of nuclear medicine and molecular imaging · 2023Article
- Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach.Journal of gastric cancer · 2023Review
- Comparison of [Canadian journal of gastroenterology & hepatology · 2023Article
- Prognostic value of the metabolic score obtained via [Scientific reports · 2022Article
- Utility of PET Scans in the Diagnosis and Management of Gastrointestinal Tumors.Digestive diseases and sciences · 2022Article
- The potential utility of [European journal of nuclear medicine and molecular imaging · 2022Article
- Article
- FAPI PET/CT in the Diagnosis of Abdominal and Pelvic Tumors.Frontiers in oncology · 2021Review
- Usefulness of [European journal of nuclear medicine and molecular imaging · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aerobic glycolysis has been the most important hypothesis in cancer metabolism. It seems to be related to increased bioenergetic and biosynthetic needs in rapidly proliferating cancer cells. To this end, F-18 fluorodeoxyglucose (FDG), a glucose analog, became widely popular for the detection of malignancies combined with positron emission tomography/computed tomography (PET/CT). Although the potential roles of FDG PET/CT in primary tumor detection are not fully established, it seems to have a limited sensitivity in detecting early gastric cancer and mainly signet ring or non-solid types of advanced gastric cancer. In evaluating lymph node metastases, the location of lymph nodes and the degree of FDG uptake in primary tumors appear to be important factors affecting the diagnostic accuracy of PET/CT. In spite of the limited sensitivity, the high specificity of PET/CT for lymph node metastases may play an important role in changing the extent of lymphadenectomy or reducing futile laparotomies. For peritoneal metastases, PET/CT seems to have a poorer sensitivity but a better specificity than CT. The roles of PET/CT in the evaluation of other distant metastases are yet to be known. Studies including primary tumors with low FDG uptake or peritoneal recurrence seem suffer from poorer diagnostic performance for the detection of recurrent gastric cancer. There are only a few reports using FDG PET/CT to predict response to neoadjuvant or adjuvant chemotherapy. A complete metabolic response seems to be predictive of more favorable prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.